A Multicenter Case-control Study of Risk Factors for Premature Ejaculation in China's Shaanxi Province

January 15, 2020 updated by: Xijing Hospital
Through a multicenter case-control study on the risk factors of premature ejaculation in Shaanxi, to find out the related factors of the occurrence and development of premature ejaculation, to provide reference for personalized treatment, in order to improve the quality of sexual life of patients and partners.

Study Overview

Status

Unknown

Conditions

Study Type

Observational

Enrollment (Anticipated)

1340

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Shaanxi
      • Xi'an, Shaanxi, China, 710032
        • Recruiting
        • Xijing Hospital, Fourth Military Medical University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 64 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Sampling Method

Non-Probability Sample

Study Population

Patients with premature ejaculation in the outpatient department of the hospital were the case group, while patients without premature ejaculation in the outpatient department were the control group

Description

Inclusion Criteria:

  • 1) case group

    1. 18-64 years old, regular sexual life > 6 months;
    2. Self-report of premature ejaculation;
    3. Able to complete questionnaires and scale scores independently. 2) control group
    1. 18-64 years old, regular sexual life > 6 months;
    2. Both partners are satisfied with their sexual life;
    3. Able to complete questionnaires and scale scores independently.

Exclusion Criteria:

  • 1) case group

    1. Those who are unable to have sex due to genital malformation;
    2. Patients with serious cardiovascular and cerebrovascular diseases;
    3. Severe mental disorders (history of epilepsy, mania, etc.);
    4. Have a history of brain trauma;
    5. People with a long history of substance abuse. 2) control group
    1. Patients with a history of mental illness;
    2. Oral selective serotonin (5-ht) reuptake inhibitors, tricyclic antidepressants, triazolidine antidepressants, tramadol and sedatives

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
IELT
Time Frame: Within 6 months
Intra-vaginal Ejaculation Latency Time
Within 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Xijing Hospital

Collaborators

First Affiliated Hospital Xi'an Jiaotong University
Shaanxi Provincial People's Hospital
Xi'an No.3 Hospital
Northwest Women's and Children's Hospital, Xi'an, Shaanxi
Shaanxi Armed Police Corps Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

July 31, 2019

Primary Completion (ANTICIPATED)

August 31, 2020

Study Completion (ANTICIPATED)

October 1, 2020

Study Registration Dates

First Submitted

January 15, 2020

First Submitted That Met QC Criteria

January 15, 2020

First Posted (ACTUAL)

January 21, 2020

Study Record Updates

Last Update Posted (ACTUAL)

January 21, 2020

Last Update Submitted That Met QC Criteria

January 15, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 4222018004

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Premature Ejaculation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe